Recruiting

Pharmacogenetics of Antidepressant-Induced Disinhibition

The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and/or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.

ClinicalTrials.gov IDNCT03953014

PhaseNot Applicable

Enrollment120

SponsorUniversity of Calgary

Age6 Years

SexALL

I'm interested View official listing

Conditions studied

Obsessive-Compulsive Disorder, Anxiety Disorders, Major Depressive Disorder, Antidepressant Drug Adverse Reaction

About this study

Primary outcomes

Genetic variants in SSRI metabolism (4 years)
Behavioural Disinhibition (4 years)

Eligibility information

Inclusion Criteria: 1. Aged 6 - 24 years 2. Medical records available 3. Diagnosis of MDD, anxiety disorder, or OCD 4. Current or past history of SSRI therapy Exclusion Criteria: 1. Inability of parent/legal guardian to give informed consent 2. Inability of the child to give informed assent 3. Unwillingness of child to provide saliva sample for genetic analysis 4. Current, past or suspected diagnosis of attention deficit hyperactivity disorder, oppositional defiant disorder, conduct disorder, bipolar disorder, psychotic disorder, or pervasive developmental disorder.

Study locations

Child and Adolescent Addiction, Mental Health & Psychiatry, Calgary, Alberta Canada

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.